The Valley Desk

Clinical trial reportJournal of clinical oncology : official journal of the American Society of Clinical OncologyPublished

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published
Subject terms
T-Lymphocytes; Humans; Kallikreins; Tissue Kallikreins; Antibodies, Bispecific; Aged; Aged, 80 and over; Middle Aged; Male; Prostatic Neoplasms, Castration-Resistant
PubMed ID
40450573
PubMed Central ID
PMC12288886
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal